Cardiovascular stress testing to diagnose patients with coronary artery disease (CAD) and other related types of conditions can be a highly-effective tool in many cases. In fact, many cardiologists ...

Genetic testing for cardiovascular disorders is rapidly expanding, including among children. In its first scientific statement focused on the issue of cardiovascular genetic testing specifically among ...

With heart disease being the leading cause of death in the USA, the goal is to identify risk factors earlier and manage your heart health over time before any complications develop. With heart disease ...

The treadmill exercise test with electrocardiogram (ECG), also known as an exercise stress test, is one of the most familiar tests in medicine. While exercise testing typically is focused on ...

Tests that look at changes in biochemistry have an important application in medicine, including point-of-care cardiac testing and monitoring heart failure. Biochemical tests can also be used to ...

Please provide your email address to receive an email when new articles are posted on . A novel genetic test may provide clues to what caused a person’s sudden cardiac death. Testing can then be ...

Cardiovascular genetic testing in children presents unique challenges, requiring pre- and post-test counseling with an individualized approach for families, ideally with the involvement of a ...

Once integration is completed, the partners plan to accelerate commercial rollout across India, anticipated in 2026.

This surprisingly simple walking test is becoming a go-to tool for measuring real cardiovascular fitness—no gym, no gadgets, no running required.

Please provide your email address to receive an email when new articles are posted on . Many adult survivors of childhood cancer are not regularly screened for cardiovascular disease. Primary ...

NT-proBNP testing should become compulsory for referring patients to specialist heart failure services to improve diagnosis, ...

Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...